- Home
- BYM vs THRD Comparison
BYM vs THRD Comparison
Compare BYM & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYM
- THRD
- Stock Information
- Founded
- BYM 2002
- THRD 2019
- Country
- BYM United States
- THRD United States
- Employees
- BYM N/A
- THRD N/A
- Industry
- BYM Investment Managers
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- BYM Finance
- THRD Health Care
- Exchange
- BYM Nasdaq
- THRD Nasdaq
- Market Cap
- BYM 273.5M
- THRD 238.7M
- IPO Year
- BYM N/A
- THRD 2022
- Fundamental
- Price
- BYM $10.47
- THRD $5.45
- Analyst Decision
- BYM
- THRD Hold
- Analyst Count
- BYM 0
- THRD 3
- Target Price
- BYM N/A
- THRD $5.00
- AVG Volume (30 Days)
- BYM 60.2K
- THRD 227.0K
- Earning Date
- BYM 01-01-0001
- THRD 08-07-2025
- Dividend Yield
- BYM 4.49%
- THRD N/A
- EPS Growth
- BYM N/A
- THRD N/A
- EPS
- BYM N/A
- THRD N/A
- Revenue
- BYM N/A
- THRD N/A
- Revenue This Year
- BYM N/A
- THRD N/A
- Revenue Next Year
- BYM N/A
- THRD N/A
- P/E Ratio
- BYM N/A
- THRD N/A
- Revenue Growth
- BYM N/A
- THRD N/A
- 52 Week Low
- BYM $9.30
- THRD $3.18
- 52 Week High
- BYM $11.77
- THRD $16.02
- Technical
- Relative Strength Index (RSI)
- BYM 49.69
- THRD 65.58
- Support Level
- BYM $10.40
- THRD $5.42
- Resistance Level
- BYM $10.62
- THRD $5.45
- Average True Range (ATR)
- BYM 0.09
- THRD 0.04
- MACD
- BYM 0.01
- THRD -0.01
- Stochastic Oscillator
- BYM 44.64
- THRD 41.67
About BYM Blackrock Municipal Income Quality Trust of Beneficial Interest
Blackrock Municipal Income Quality Trust is a closed-end municipal bond fund. Its investment objective is to provide current income exempt from U.S. federal income taxes, including the alternative minimum tax. The trust invests in various sectors such as transportation, utilities, health, education, corporate, housing, and others.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.